查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016266

家禽疫苗市场：2026-2032年全球市场预测（按产品类型、物种、给药途径、最终用户和分销管道划分）

Poultry Vaccine Market by Product Type, Species, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，家禽疫苗市场价值将达到 28.5 亿美元，到 2026 年将成长到 30 亿美元，到 2032 年将达到 43.7 亿美元，复合年增长率为 6.26%。

主要市场统计数据
基准年 2025 28.5亿美元
预计年份：2026年 30亿美元
预测年份：2032年 43.7亿美元
复合年增长率 (%) 6.26%

对不断发展的家禽疫苗生态系统进行了简洁且权威的概述，将科学创新、生产需求和商业性重点联繫起来。

受科学创新、生产模式转变以及生物安全期望不断提高的驱动，家禽疫苗领域正在迅速发展。本执行摘要整合了影响全球家禽系统疫苗研发和部署的关键主题，为产业领导者提供了一个连结科学、政策和商业的全面观点。本概要重点在于技术进步、监管变化、供应链趋势和终端用户行为，所有这些因素共同决定了疫苗研发者、经销商和家禽生产商决策的优先事项。

科学、监管和营运创新的融合如何加速家禽系统平台多样化和综合疫苗接种策略？

现代家禽疫苗接种格局正受到多种变革力量的共同影响而重塑，这些力量在加速创新的同时，也暴露出系统性脆弱性。首先，平台多样化正在加速发展，重组技术和核酸技术正从实验阶段走向商业性实用化。与传统的减毒或灭活疫苗相比，这种转变能够产生更具针对性的免疫反应，缩短研发週期，并改变疫苗研发管线和研发人员的投资策略。

关税引发的贸易摩擦如何推动了疫苗价值链全过程的供应链重组、区域生产策略调整和物流优化？

美国近期加征的关税累积效应，为疫苗生产商、供应商和分销网络带来了一系列复杂的挑战和战略转折点。关税提高了依赖进口的生产商取得某些原料和成品的成本，促使其进行供应链重组并增强采购韧性。为此，许多相关人员正在加快供应商认证流程，并发展符合品质和监管要求的区域供应商，以降低关税波动带来的风险。

一个多维细分框架，明确了目标策略中使用的产品平台的选择、管理方法、每种类型的需求以及分销管道。

细分市场层面的差异化对于了解整个家禽疫苗市场的采用趋势和投资重点至关重要。从产品类型来看，灭活疫苗和减毒活病毒疫苗等传统平台在安全性和有效性已得到验证的细分市场中仍然发挥着重要作用，而重组疫苗因其模组化和适应性而备受关注。在重组疫苗领域，mRNA平台、蛋白质次单元构建体和病毒载体系统分别代表不同的研发管道和生产​​结构。即使在病毒载体内部，腺病毒、甲病毒和痘病毒骨架之间也存在技术差异，每种骨架都具有独特的免疫抗原性和生产特性，这会影响研发人员的选择和最终用户的适用性。

生产规模、监管方式和物流现实的区域差异如何影响全球疫苗的选择和部署策略？

区域趋势对整个家禽生产系统的疫苗研发重点、采购行为、监管方法和分销体係都具有决定性影响。美洲地区拥有成熟的商业家禽产业，其特点是生物安全规程高度整合、自动化给药技术广泛应用以及对生产力指标的高度重视。在此背景下，商业生产者积极投资于高效平台，以实现规模经济、获得监管认可，并在生产力和禽群健康方面取得可预测的成果，从而推动创新。

竞争定位和伙伴关係策略揭示了竞争製造商和生物技术创新者如何塑造疫苗供应和附加价值服务。

家禽疫苗产业的竞争动态呈现出传统生技药品专家、生物技术创新者和灵活敏捷的区域性开发商并存的态势，各方都凭藉其平台专长、分销网络和监管记录占据着各自的战略地位。成熟的疫苗生产商在规模化生产、检验的低温运输物流和庞大的安全资料库方面保持优势，这些优势有助于获得监管部门的核准，并让商业客户安心。同时，专注于重组和核酸平台的新兴生物技术参与企业正在重塑创新前沿，它们展现出快速的候选疫苗优化、平台模组化和跨病原体适应性。

采取具体且优先的企业措施，以加速平台适应性，增强供应链韧性，并扩大在各种生产系统中的商业性应用。

产业领导企业可以采取多项切实可行的措施来增强自身韧性，加速创新成果的实用化，并扩大其在禽类市场的商业性影响力。首先，在开发平臺中优先考虑平台无关功能，以实现快速抗原交换和跨病原体反应。模组化平台能够在不影响监管合规性的前提下，降低应对新发感染疾病征兆所需的时间和成本。其次，投资优化给药系统，例如气雾剂、喷雾剂和口服给药系统，以降低给药成本，并促进这些系统在面临严重劳动力短缺的高密度生产系统中得到应用。

为了得出策略性结论，我们采用了高度透明、以证据为基础的调查方法，结合了专家访谈、文献检验和情境压力测试。

本执行摘要的研究是基于结构化、多维度的调查方法，旨在产生可重复的洞见，并揭示对相关人员的实际意义。主要资讯来源包括对疫苗研发、兽医学和家禽生产领域专家的深入访谈，以及与重组和核酸平台开发人员的技术简报。二级资讯来源包括同侪审查的科学文献、监管指导文件、产业白皮书和供应链物流分析，从而能够对趋势进行三角检验，并检验营运限制因素。

综合策略结论强调，在技术、商业和供应方面采取统一的韧性方法，对于最大限度地提高疫苗的有效性至关重要。

当前家禽疫苗接种的发展趋势为能够将技术创新与切实可行的分销和生产策略相结合的相关人员提供了明确的机会。重组疫苗平台和先进的给药方法不再是边缘因素，而是成为生产者和监管机构在疾病预防和生产连续性方面考虑的核心要素。同时，贸易政策的变化和物流限制凸显了建立具有韧性的供应链和灵活的商业化模式的必要性，以应对快速的市场波动和长期的结构性变化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 家禽疫苗市场：依产品类型划分

  • DNA
  • 失活
  • 减毒活病毒疫苗
  • 重组
    • mRNA
    • 蛋白质次单元
    • 病毒载体
      • 腺病毒
      • 甲病毒
      • 痘病毒
  • 次单元

第九章 家禽疫苗市场：依类型划分

  • 鸡
  • 鸭子
  • 火鸡

第十章：家禽疫苗市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 皮下
  • 口服
  • 喷
    • 气雾剂
    • 喷

第十一章 家禽疫苗市场：依最终用户划分

  • 家庭养鸡场
  • 商业农场
    • 肉鸡养殖场
    • 蛋鸡养殖场
  • 研究机构

第十二章 家禽疫苗市场：依通路划分

  • 线上管道
    • EC市场
    • 製造商网站
  • 动物医院
    • 公立医院
    • 私立医院
  • 兽药
    • 连锁药局
    • 独立经营药房

第十三章 家禽疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 家禽疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 家禽疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国家禽疫苗市场

第十七章：中国家禽疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AniCon Labor GmbH
  • Boehringer Ingelheim Animal Health GmbH
  • Ceva Sante Animale SA
  • Elanco Animal Health Incorporated
  • HIPRA, SAU
  • Indian Immunologicals Limited
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vaxxinova Group BV
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-0375F3EA9C41

The Poultry Vaccine Market was valued at USD 2.85 billion in 2025 and is projected to grow to USD 3.00 billion in 2026, with a CAGR of 6.26%, reaching USD 4.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.85 billion
Estimated Year [2026] USD 3.00 billion
Forecast Year [2032] USD 4.37 billion
CAGR (%) 6.26%

A concise and authoritative synthesis of the evolving poultry vaccine ecosystem connecting scientific innovation, production imperatives, and commercial priorities

The poultry vaccine landscape is undergoing rapid evolution driven by scientific innovation, changing production models, and heightened biosecurity expectations. This executive summary synthesizes critical themes shaping vaccine development and deployment across global poultry systems, offering leaders a consolidated perspective that bridges science, policy, and commerce. The narrative focuses on technological trajectories, regulatory inflections, supply chain dynamics, and end-user behavior that together define decision-making priorities for vaccine developers, distributors, and poultry producers.

In recent years, advancements in recombinant technologies and precision delivery mechanisms have begun to redefine the risk-benefit calculus for vaccination programs. Concurrently, producers face increasing pressure to adopt solutions that balance efficacy, cost efficiency, and operational compatibility with intensive production systems. As a result, research and commercial efforts are shifting toward platforms that can be scaled, adapted to shifting pathogen landscapes, and integrated with digital health monitoring systems. The introduction frames subsequent sections by outlining how transformative shifts, trade dynamics, segmentation nuances, regional patterns, competitive positioning, and recommended actions intersect to inform robust strategic planning for stakeholders across the poultry vaccine value chain.

How converging scientific, regulatory, and operational innovations are accelerating platform diversification and integrated vaccination strategies across poultry systems

The contemporary landscape of poultry vaccination is being reshaped by several convergent transformative forces that accelerate innovation while exposing systemic vulnerabilities. First, platform diversification has gained momentum, with recombinant approaches and nucleic acid technologies moving from experimental stages toward commercial viability. This shift is enabling more targeted immune responses and shorter development cycles relative to classical attenuated or inactivated approaches, altering vaccine pipelines and developer investment strategies.

Second, delivery innovations are changing adoption dynamics on farms. Non-invasive routes such as aerosolized sprays and optimized oral formulations are improving ease of administration for large flocks and reducing labor burdens, which in turn is producing stronger demand from commercial producers seeking operational efficiencies. Third, regulatory landscapes are progressively evolving to accommodate novel biologics, prompting more harmonized frameworks in some jurisdictions while creating intermittent uncertainty in others. This regulatory heterogeneity incentivizes developers to design platforms with cross-border adaptability.

Fourth, digital tools and diagnostics are increasingly linked to vaccination strategies, enabling real-time monitoring of immune response and outbreak signals, and thereby making vaccination decisions more data-driven. Finally, heightened emphasis on animal welfare and antimicrobial stewardship is pushing vaccines to the forefront as both preventive health tools and alternatives to therapeutic antibiotic use. Collectively, these shifts indicate a transition toward smarter, more integrated vaccination ecosystems in poultry production.

How tariff-driven trade frictions have catalyzed supply chain reconfiguration, regional production strategies, and logistics optimization across the vaccine value chain

The cumulative impact of recent tariff actions originating from the United States has introduced a complex set of headwinds and strategic inflection points for vaccine producers, suppliers, and distribution networks. Tariff measures have increased the landed cost of selected inputs and finished goods for import-dependent manufacturers, prompting supply chain reconfiguration and an increased emphasis on sourcing resilience. In response, many stakeholders have accelerated supplier qualification processes and explored regional suppliers with compatible quality and regulatory credentials to mitigate exposure to tariff volatility.

Moreover, tariff-driven cost pressures have amplified the importance of cold-chain optimization and inventory management. Organizations with robust logistics capabilities have been able to absorb short-term cost shocks by streamlining transport consolidation, renegotiating freight terms, and leveraging longer lead times to smooth procurement cycles. Conversely, smaller manufacturers and independent distributors have experienced margin compression, which in turn has encouraged strategic partnerships, co-manufacturing arrangements, and selective vertical integration to preserve access and continuity of supply.

Trade policy adjustments have also accelerated conversations about nearshoring and regional manufacturing hubs as long-term solutions to tariff risk. Investors and executives are increasingly evaluating the trade-offs between capital expenditure for localized capacity and the ongoing softening of cross-border trade flows. In parallel, regulatory compliance and quality assurance remain pivotal as jurisdictions adapt their import-review processes, underscoring the need for transparent documentation and harmonized standards to sustain cross-border vaccine availability despite tariff-related disruptions.

A multidimensional segmentation framework that clarifies product platform choice, delivery modalities, species-specific needs, and distribution pathways for targeted strategies

Segment-level differentiation is central to understanding adoption dynamics and investment priorities across the poultry vaccine landscape. Product type segmentation reveals that traditional platforms such as inactivated and live attenuated vaccines continue to play key roles where established safety and efficacy profiles exist, while recombinant categories are attracting substantial attention for their modularity and adaptability. Within recombinant approaches, mRNA platforms, protein subunit constructs, and viral vector systems demonstrate distinct development pathways and manufacturing footprints. Viral vectors themselves show further technical differentiation across adenovirus, alphavirus, and poxvirus backbones, each bringing specific immunogenic and production characteristics that influence developer choice and end-user suitability.

Species segmentation-spanning chickens, ducks, and turkeys-affects antigen selection, delivery methods, and vaccination schedules because each species presents unique husbandry practices and disease exposure patterns. Route of administration is another critical axis: injectable formats, delivered intramuscularly or subcutaneously, remain prevalent where precise dosing and systemic immunity are priorities, while oral and spray routes, including aerosol and fogging spray modalities, offer practical advantages for mass administration and labor-constrained operations. End-user segmentation distinguishes backyard operations, commercial farms, and research institutions, with commercial broiler and layer farms requiring scalable, cost-effective solutions that integrate into high-throughput production systems, whereas backyard settings prioritize ease of use and minimal cold-chain dependency. Distribution channel segmentation complements these distinctions by shaping access and service models; online channels through e-commerce marketplaces and manufacturer websites offer broader reach and convenience, veterinary hospitals-both government and private-provide clinical oversight and product stewardship, and veterinary pharmacies, whether chain or independent, facilitate localized access and point-of-care advice. These interacting segmentation dimensions create a multidimensional framework for prioritizing R&D investments, tailoring commercialization strategies, and designing distribution partnerships that align with end-user needs and operational realities.

How diverse regional production intensities, regulatory approaches, and logistical realities shape vaccine preferences and deployment strategies globally

Regional dynamics exert a defining influence on vaccine development priorities, procurement behavior, regulatory approaches, and distribution architectures across poultry production systems. The Americas region is characterized by a mature commercial poultry industry with advanced integration of biosecurity protocols, broad use of automated administration technologies, and a strong emphasis on productivity metrics. In this context, innovation is driven by scale efficiencies, regulatory reliability, and commercial producers' willingness to invest in high-efficacy platforms that deliver predictable returns in performance and flock health.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization varies and resource availability ranges widely. In several European markets, stringent regulatory frameworks and strong animal welfare norms favor licensed, well-characterized vaccines and comprehensive surveillance programs. In parts of the Middle East and Africa, vaccination strategies must reconcile logistical constraints, fragmented cold chains, and diverse production systems, which increases demand for thermostable formulations and simplified delivery options.

Asia-Pacific hosts some of the fastest-evolving production systems and high-density poultry populations, driving intensive focus on scalable delivery mechanisms, rapid-response platforms, and regionally tailored antigen panels to address endemic and emerging threats. Cross-border trade, dense production clusters, and strong governmental investment in disease control amplify the urgency for adaptable vaccine solutions that can be deployed at scale while aligning with local regulatory and manufacturing capacities. Across all regions, regional policy shifts, zoonotic risk awareness, and localized production imperatives influence procurement timelines and product performance expectations.

Competitive positioning and partnership strategies that reveal how legacy manufacturers and biotech innovators are shaping vaccine availability and value-added services

Competitive dynamics in the poultry vaccine sector reflect a mix of legacy biologics specialists, biotech innovators, and nimble regional developers, each occupying strategic positions based on platform expertise, distribution reach, and regulatory track record. Established vaccine manufacturers retain advantages in large-scale production, validated cold-chain logistics, and extensive safety databases that ease regulatory approvals and reassure commercial customers. At the same time, biotech entrants focusing on recombinant and nucleic acid platforms are reshaping the innovation frontier by demonstrating faster candidate iteration, platform modularity, and potential for cross-pathogen adaptability.

Partnership models are increasingly prominent; collaborations between research institutions and commercial entities accelerate translational pathways, while co-manufacturing and licensing agreements expand production capacity and geographic reach. Distribution strategies vary from direct-to-producer engagement in highly integrated markets to channel partnerships with veterinary hospitals and pharmacies in markets where clinical oversight is crucial. Strategic differentiators include proprietary adjuvant technologies, thermostability innovations, and validated delivery systems that reduce administration complexity. In addition, companies investing in data integration-linking vaccination events with flock health records and diagnostic outcomes-are positioned to offer value-added services that deepen customer relationships and create sticky revenue streams through service subscriptions and analytics.

Concrete and prioritized measures for companies to accelerate platform adaptability, strengthen supply resilience, and expand commercial adoption across diverse production systems

Industry leaders can adopt several actionable steps to strengthen resilience, accelerate innovation translation, and expand commercial impact across poultry markets. First, prioritize platform-agnostic capabilities in development pipelines to enable faster antigen swaps and cross-pathogen responsiveness; modular platforms reduce time and cost to adapt to emergent disease signals without compromising regulatory compliance. Second, invest in delivery system optimization, including aerosol, fogging, and oral modalities, to lower administration costs and increase adoption in high-density production systems where labor constraints are acute.

Third, reinforce supply chain resilience by diversifying input sources, qualifying regional contract manufacturers, and expanding thermostable product lines to reduce cold-chain dependence. Fourth, pursue strategic partnerships that combine technical innovation with distribution strength, such as licensing arrangements, co-manufacturing, and data-sharing agreements with diagnostic providers to create closed-loop health solutions. Fifth, engage proactively with regulators and industry bodies to support harmonized dossiers and to pilot adaptive approval pathways for platform technologies. Finally, align commercial models with end-user realities by offering bundled services-training, monitoring, and outcome analytics-that translate product efficacy into operational value and make vaccination investments easier to justify for producers with differing scales and capacities. Implementing these measures will improve speed-to-market, adoption rates, and long-term sustainability across varied production landscapes.

A transparent evidence-based methodology combining expert interviews, literature triangulation, and scenario stress tests to inform strategic conclusions

The research underpinning this executive summary relies on a structured, multi-source methodology designed to produce replicable insights and to surface practical implications for stakeholders. Primary inputs included in-depth interviews with subject-matter experts across vaccine R&D, veterinary practice, and poultry production, supplemented by technical briefings with developers of recombinant and nucleic acid platforms. Secondary sources encompassed peer-reviewed scientific literature, regulatory guidance documents, industry whitepapers, and supply chain logistics analyses to triangulate trends and validate operational constraints.

Analytical methods combined qualitative synthesis with scenario-based stress testing to explore the ramifications of trade and regulatory shifts on supply continuity and product deployment. The approach emphasized cross-validation of claims through multiple evidence streams to reduce bias and to ensure findings reflect operational realities rather than aspirational projections. Limitations are acknowledged where data gaps exist, particularly around proprietary clinical performance metrics and confidential commercial arrangements. To mitigate this, the methodology prioritized transparency in assumptions, documented data provenance, and recommended targeted follow-up engagements to drill deeper into areas requiring quantitative verification or bespoke local intelligence.

Synthesis of strategic conclusions emphasizing the imperative for integrated technological, commercial, and supply resilience actions to realize vaccine impact

The current trajectory of poultry vaccination signals a clear opportunity for stakeholders who can integrate technological innovation with pragmatic distribution and production strategies. Recombinant platforms and advanced delivery methods are no longer peripheral; they are becoming central to how producers and regulators think about disease prevention and production continuity. At the same time, trade policy shifts and logistical constraints underscore the need for resilient supply architectures and agile commercialization models that can adapt to both acute disruptions and longer-term structural changes.

Decision-makers should therefore balance investments across near-term operational gains-such as thermostability and simplified administration-and longer-term platform development that enables rapid response to emerging pathogens. Cross-sector collaboration, including public-private partnerships and alliances with diagnostic and digital health providers, will be instrumental in converting vaccine efficacy into measurable flock health outcomes. By aligning R&D priorities, regulatory engagement, and distribution strategies, stakeholders can accelerate the transition from proof-of-concept innovations to widely adopted, field-ready solutions that enhance biosecurity and producer profitability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Poultry Vaccine Market, by Product Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. Recombinant
    • 8.4.1. mRNA
    • 8.4.2. Protein Subunit
    • 8.4.3. Viral Vector
      • 8.4.3.1. Adenovirus
      • 8.4.3.2. Alphavirus
      • 8.4.3.3. Poxvirus
  • 8.5. Subunit

9. Poultry Vaccine Market, by Species

  • 9.1. Chicken
  • 9.2. Duck
  • 9.3. Turkey

10. Poultry Vaccine Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
  • 10.3. Spray
    • 10.3.1. Aerosol
    • 10.3.2. Fogging

11. Poultry Vaccine Market, by End User

  • 11.1. Backyard Farms
  • 11.2. Commercial Farms
    • 11.2.1. Broiler Farms
    • 11.2.2. Layer Farms
  • 11.3. Research Institutes

12. Poultry Vaccine Market, by Distribution Channel

  • 12.1. Online Channels
    • 12.1.1. E Commerce Marketplaces
    • 12.1.2. Manufacturer Websites
  • 12.2. Veterinary Hospitals
    • 12.2.1. Government Hospitals
    • 12.2.2. Private Hospitals
  • 12.3. Veterinary Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Poultry Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Poultry Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Poultry Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Poultry Vaccine Market

17. China Poultry Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AniCon Labor GmbH
  • 18.6. Boehringer Ingelheim Animal Health GmbH
  • 18.7. Ceva Sante Animale S.A.
  • 18.8. Elanco Animal Health Incorporated
  • 18.9. HIPRA, S.A.U.
  • 18.10. Indian Immunologicals Limited
  • 18.11. Merck & Co., Inc.
  • 18.12. Phibro Animal Health Corporation
  • 18.13. Vaxxinova Group B.V.
  • 18.14. Virbac S.A.
  • 18.15. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POULTRY VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POULTRY VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POULTRY VACCINE MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POULTRY VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POULTRY VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POULTRY VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POULTRY VACCINE MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POULTRY VACCINE MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POULTRY VACCINE MARKET SIZE, BY ALPHAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POULTRY VACCINE MARKET SIZE, BY POXVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POULTRY VACCINE MARKET SIZE, BY DUCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POULTRY VACCINE MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POULTRY VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POULTRY VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POULTRY VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POULTRY VACCINE MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POULTRY VACCINE MARKET SIZE, BY FOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POULTRY VACCINE MARKET SIZE, BY BACKYARD FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POULTRY VACCINE MARKET SIZE, BY BROILER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POULTRY VACCINE MARKET SIZE, BY LAYER FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POULTRY VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POULTRY VACCINE MARKET SIZE, BY E COMMERCE MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POULTRY VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POULTRY VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POULTRY VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POULTRY VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POULTRY VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POULTRY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL POULTRY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 251. GCC POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 252. GCC POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GCC POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GCC POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 293. G7 POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 294. G7 POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. G7 POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. G7 POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 304. NATO POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. NATO POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 307. NATO POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 308. NATO POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 309. NATO POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. NATO POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. NATO POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. NATO POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 317. NATO POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL POULTRY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA POULTRY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA POULTRY VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA POULTRY VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA POULTRY VACCINE MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA POULTRY VACCINE MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA POULTRY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA POULTRY VACCINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA POULTRY VACCINE MARKET SIZE, BY SPRAY, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA POULTRY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA POULTRY VACCINE MARKET SIZE, BY COMMERCIAL FARMS, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA POULTRY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA POULTRY VACCINE MARKET SIZE, BY ONLINE CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA POULTRY VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA POULTRY VACCINE MARKET SIZE, BY VETERINARY PHARMACIES, 2018-2032 (USD MILLION)